MHRA APPROVES REPEAT USE OF DOVOBET® FOR PSORIASIS
LEO Pharma announced today that the MHRA has approved the repeat use of Dovobet® the only topical treatment containing the vitamin D analogue calcipotriol and a corticosteroid for the treatment of plaque psoriasis. This follows the assessment of a long term safety study reported in 2005.1
Dovobet® should be applied to the affected area once daily. The recommended treatment period is 4 weeks. After this period repeated treatment with Dovobet® can be initiated under medical supervision.
"Dovobet® has rapidly established itself as the first line combination treatment for plaque psoriasis” said Dr Sandeep Cliff, Consultant Dermatologist at Crawley Hospital. "Many patients gain benefit quickly within four weeks but there are those who do need the option for longer treatment to keep their psoriasis under control as and when needed. This new flexibility is great news”, he added.
-THE END-
For further information please contact:
Lucy Howell
Athena Medical PR
Tel: 020 8956 2298
[email protected]
Marian Molloy
Athena Medical PR
Tel: 020 8956 2865
[email protected]
Notes to editors
References
LEO Pharma announced today that the MHRA has approved the repeat use of Dovobet® the only topical treatment containing the vitamin D analogue calcipotriol and a corticosteroid for the treatment of plaque psoriasis. This follows the assessment of a long term safety study reported in 2005.1
Dovobet® should be applied to the affected area once daily. The recommended treatment period is 4 weeks. After this period repeated treatment with Dovobet® can be initiated under medical supervision.
"Dovobet® has rapidly established itself as the first line combination treatment for plaque psoriasis” said Dr Sandeep Cliff, Consultant Dermatologist at Crawley Hospital. "Many patients gain benefit quickly within four weeks but there are those who do need the option for longer treatment to keep their psoriasis under control as and when needed. This new flexibility is great news”, he added.
For further information please contact:
Lucy Howell
Athena Medical PR
Tel: 020 8956 2298
[email protected]
Marian Molloy
Athena Medical PR
Tel: 020 8956 2865
[email protected]
Notes to editors
- A recently launched report, Making Psoriasis a Priority, authored by patient organisations and leading experts, highlighted the plight of the 1.2 million people in the UK with psoriasis and led to calls for improved standards of care and support for people living with the condition.3
- Psoriasis can impair quality of life to the same degree as diabetes, heart disease and some cancers.4
- Chronic plaque psoriasis is the most common form and it is characterised by raised red plaques which are often painful, itchy and unsightly.5
- In vitro data suggests that calcipotriol (Vitamin D analogue) induces differentiation and suppresses proliferation of keratinocytes. Like other corticosteroids, betamethasone dipropionate has anti-inflammatory, antipruritic, vasoconstrictive and immunosuppressive properties, however, without curing the underlying condition.6
References
- Kragballe K, Bibby AJ, Jolliffe D. A 52-week randomised safety study of a calcipotriol / betamethasone dipropionate two-compound product in the treatment of psoriasis vulgaris. Abstract provided by LEO Pharma.
- www.scottishmedicines.org.uk; Scottish Medicines Consortium
- Making psoriasis a priority 2005. Sponsored by LEO Pharma
- Rapp S, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology 1999; 41: 401-7
- Health Technology Assessment 2000; 4: 40
- www.emc.medicines.org.uk; Dovobet® Ointment SPC